Skip to content
Search

Latest Stories

NICE seeks feedback on annual BMI checks for adults with long-term conditions

Regular monitoring of BMI and waist-to-height ratio is a "powerful tool" to help prevent type 2 diabetes and heart disease.

NICE calls for annual BMI checks for adults with long-term conditions

Annual BMI measurements create early intervention opportunities for weight management

Getty Images

The National Institute for Health and Care Excellence (NICE) has published a draft quality standard recommending annual Body mass index (BMI) and waist-to-height measurements for adults with long-term conditions to help prevent weight-related complications.

A consultation has been launched to gather feedback from healthcare professionals and commissioners on the feasibility of implementing these proposals within the NHS.


The draft quality standard calls for yearly BMI measurements for all patients with long-term conditions and additional waist-to-height measurements for those with a BMI below 35.

NICE stated that these annual measurements will help identify individuals at risk of weight-related complications earlier, enabling them to receive timely support to prevent future health issues.

Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, explained: “These simple annual measurements create opportunities for early intervention and conversations about long-term health and wellbeing.”

“By identifying trends before they become problems, clinical practitioners can help people prevent more serious health complications down the line.”

He emphasised that tracking BMI and waist-to-height ratio annually is “a powerful tool” in preventing conditions such as type 2 diabetes, heart disease, and other obesity-related health issues.

Currently, while people with long-term conditions undergo routine physical health checks, BMI and waist-to-height measurements are not consistently recorded.

NICE’s new approach aims to address this inequality in care.

Its draft quality standard focuses on adults with conditions such as COPD, diabetes, heart failure, learning disabilities, rheumatoid arthritis, schizophrenia, and stroke, though this isn't a definitive list.

“We want to hear from healthcare professionals and commissioners during the consultation period to understand whether the proposals we've made can be implemented in the NHS,” said Dr Rebecca Payne, GP and chair of quality standards advisory committee at NICE.

NICE’s draft quality standard also stresses the importance of improving access to weight management services for people with learning disabilities, providing information on available interventions, and ensuring follow-up care for those prescribed weight management medicines or discharged from bariatric surgery services.

The consultation, which opened on 18 March, will run until 15 April 2025, with the final quality standard expected in August 2025.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less